Physician profile
Xin Tan
NPI 1609239490
$800.35
in general payments reported to CMS, 2019-2025
15 companies · $111 in 2025
The $111 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.30 · 2020: $51.67 · 2021: $74.60 · 2022: $155 · 2023: $170 · 2024: $227 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $140.87 | 2022-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Madrigal Pharmaceuticals | $135.15 | 2024 | Rezdiffra |
| Glaxosmithkline, LLC. | $80.95 | 2020-2025 | Bexsero |
| Corium, LLC | $74.21 | 2022-2025 | Azstarys |
| Opko Pharmaceuticals, LLC | $63.22 | 2022 | |
| Tris Pharma INC | $59.46 | 2020-2021 | |
| Sobi, INC | $49.99 | 2020-2024 | |
| Sanofi Pasteur INC. | $49.10 | 2019-2024 | |
| Cranial Technologies, INC | $33.08 | 2024-2025 | Doc Band |
| Novartis Pharmaceuticals Corporation | $27.08 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.58 | 2023 | Jynarque |
| Pfizer INC. | $19.11 | 2023 | |
| Ironshore Pharmaceuticals INC. | $16.37 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.18 | 2023 | Flumist Quadrivalent |
| Takeda Pharmaceuticals U.S.A., INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xin Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.